These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25424470)

  • 21. Targeted treatments for fragile X syndrome.
    Berry-Kravis E; Knox A; Hervey C
    J Neurodev Disord; 2011 Sep; 3(3):193-210. PubMed ID: 21484200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intellectual functioning and behavioural features associated with mosaicism in fragile X syndrome.
    Baker EK; Arpone M; Vera SA; Bretherton L; Ure A; Kraan CM; Bui M; Ling L; Francis D; Hunter MF; Elliott J; Rogers C; Field MJ; Cohen J; Maria LS; Faundes V; Curotto B; Morales P; Trigo C; Salas I; Alliende AM; Amor DJ; Godler DE
    J Neurodev Disord; 2019 Dec; 11(1):41. PubMed ID: 31878865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
    Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
    Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fragile X syndrome: From protein function to therapy.
    Bagni C; Oostra BA
    Am J Med Genet A; 2013 Nov; 161A(11):2809-21. PubMed ID: 24115651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations of visual and auditory evoked potentials in fragile X syndrome.
    Knoth IS; Vannasing P; Major P; Michaud JL; Lippé S
    Int J Dev Neurosci; 2014 Aug; 36():90-7. PubMed ID: 24875778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of the psychiatric problems associated with fragile X syndrome.
    Hagerman RJ; Polussa J
    Curr Opin Psychiatry; 2015 Mar; 28(2):107-12. PubMed ID: 25602250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of ultrasonic vocalizations of Fragile X mice.
    Belagodu AP; Johnson AM; Galvez R
    Behav Brain Res; 2016 Sep; 310():76-83. PubMed ID: 27142239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early identification of autism in fragile X syndrome: a review.
    McCary LM; Roberts JE
    J Intellect Disabil Res; 2013 Sep; 57(9):803-14. PubMed ID: 22974167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FMR1 gene and fragile X syndrome.
    Bardoni B; Mandel JL; Fisch GS
    Am J Med Genet; 2000; 97(2):153-63. PubMed ID: 11180223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.
    Brasa S; Mueller A; Jacquemont S; Hahne F; Rozenberg I; Peters T; He Y; McCormack C; Gasparini F; Chibout SD; Grenet O; Moggs J; Gomez-Mancilla B; Terranova R
    Clin Epigenetics; 2016; 8():15. PubMed ID: 26855684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and maternal predictors of cognitive and behavioral trajectories in females with fragile X syndrome.
    Del Hoyo Soriano L; Thurman AJ; Harvey DJ; Ted Brown W; Abbeduto L
    J Neurodev Disord; 2018 Jun; 10(1):22. PubMed ID: 29925305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma Levels of Leptin and Adiponectin in Fragile X Syndrome.
    Lisik MZ; Gutmajster E; Sieroń AL
    Neuroimmunomodulation; 2016; 23(4):239-243. PubMed ID: 27902989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome.
    Wheeler A; Raspa M; Bann C; Bishop E; Hessl D; Sacco P; Bailey DB
    Am J Med Genet A; 2014 Jan; 164A(1):141-55. PubMed ID: 24352914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The psychiatric presentation of fragile x: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome.
    Tranfaglia MR
    Dev Neurosci; 2011; 33(5):337-48. PubMed ID: 21893938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rates of protein synthesis are reduced in peripheral blood mononuclear cells (PBMCs) from fragile X individuals.
    Dionne O; Lortie A; Gagnon F; Corbin F
    PLoS One; 2021; 16(5):e0251367. PubMed ID: 33974659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic modifications in human fragile X pluripotent stem cells; Implications in fragile X syndrome modeling.
    Gerhardt J
    Brain Res; 2017 Feb; 1656():55-62. PubMed ID: 26475977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elimination disorders in persons with Prader-Willi and Fragile-X syndromes.
    Equit M; Piro-Hussong A; Niemczyk J; Curfs L; von Gontard A
    Neurourol Urodyn; 2013 Sep; 32(7):986-92. PubMed ID: 23239431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling fragile X syndrome in the laboratory setting: A behavioral perspective.
    Melancia F; Trezza V
    Behav Brain Res; 2018 Sep; 350():149-163. PubMed ID: 29704597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of mavoglurant and its potential for the treatment of fragile X syndrome.
    Gomez-Mancilla B; Berry-Kravis E; Hagerman R; von Raison F; Apostol G; Ufer M; Gasparini F; Jacquemont S
    Expert Opin Investig Drugs; 2014 Jan; 23(1):125-34. PubMed ID: 24251408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensory Processing Phenotypes in Fragile X Syndrome.
    Rais M; Binder DK; Razak KA; Ethell IM
    ASN Neuro; 2018; 10():1759091418801092. PubMed ID: 30231625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.